Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clesacostat and Ervogastat in NAFLD
NCT03776175Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ervogastat, clesacostat in non-alcoholic fatty liver disease (NAFLD), sponsored by Pfizer. Started Jan 2019; status: completed.
02
Drugs
ervogastatclesacostat
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03776175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776175.